Navigation Links
Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
Date:11/6/2010

th Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate." The poster, 1096, will be presented in poster session B by Vibeke Strand, M.D., clinical professor of medicine at Stanford University in Palo Alto, Calif.

About Rheumatoid ArthritisRheumatoid arthritis (RA) is a systemic, chronic autoimmune disease characterized by inflammation in the lining of joints (or synovium), causing joint damage with chronic pain, stiffness, swelling and fatigue. RA causes limited range of motion and decreased function as a result of affected joints losing their shape and alignment.

RA affects about 1 percent of the world's population, including more than 1 million people in the United States. The condition is more common in women than in men, who account for 75 percent of patients diagnosed with RA.

About Alder BiopharmaceuticalsAlder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. ALD518 is an investigational monoclonal antibody to the pro-inflammatory cytokine IL-6 that is being developed by Bristol-Myers Squibb for autoimmune indications. In addition to Bristol-Myers Squibb, partners include Merck and Genmab. For more information, visit www.alderbio.com.Media Contact: Ian Stone or David SchullRusso PartnersTel: +1 619-528-2220ian.stone@russopartnersllc.comdavid.schull@russopartnersllc.com
'/>"/>

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. Encision Enters Into Sales Representation Agreement With Caldera Medical
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
5. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
6. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
7. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
8. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
9. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
11. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) announced today ... serve in a newly created position of Senior Vice ... be responsible for managing the operations of Bio-Techne,s Protein ... in July 2014 and the recently acquired CyVek business. ... ProteinSimple develops and commercializes proprietary systems and consumables that ...
(Date:11/24/2014)... WASHINGTON , Nov. 24, 2014  Last ... G.K. Butterfield (D-NC) took a bold ... diseases by introducing the OPEN Act. Original co-sponsors ... Hastings (D-FL). The Act will incentivize drug makers ... life-threatening rare diseases and pediatric cancers, which opens ...
(Date:11/24/2014)... 2014 Continental Clinical Solutions, LLC ... clinical trials at its mid-Atlantic late-phase research facility, ... created with the idea of closing patient disparities ... in medical advances," said Continental's CEO, Saleh ... the immortal cell line of Henrietta Lacks, dubious ...
(Date:11/23/2014)... St. Francis, WI (PRWEB) November 23, 2014 ... based manufacturer and supplier of fine chemical ingredients ... industries announced the launch of its new website, ... a description of Apiscent Labs, clean design, easy ... qualities that make Apiscent Labs stand out. ...
Breaking Biology Technology:Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... coming out of California, but the failure of flight communications ... of the weirdest. , ,The radio system used by controllers ... snit when its regular monthly maintenance wasnt performed and shut ... couldnt talk to them, even as the planes converged well ...
... raised the premise that in the early years of biotech it ... health care. , ,Theres a thread drawn to the early ... making money but about expressing what was going on in society ... money and both have become industries that have become mainstream. , ...
... likely be a popular spot for wireless use. Source: Fitchburg ... green mixed-use development, is now home to a free wireless ... Systems put up, provides wireless access to about 16 ... prairie with trails and a large pavilion. , ,Besides Berbee, ...
Cached Biology Technology:Proactive nightmares 2Biotech IPOs bring in encouraging sums 2Biotech IPOs bring in encouraging sums 3Fitchburg tech campus offers free wireless access 2
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... Nov. 3, 2014 Research and Markets ... Therapy - Technologies, Markets and Companies" to their offering. ... technologies and methods, which have already started to play an ... transplantation is replacing the old fashioned bone marrow transplants. Role ... is bound to become a part of medical practice. ...
(Date:11/3/2014)... Researchers from Australia report that low birth weight and ... (OA)-related hip replacements in adulthood. Findings published in the ... & Research , indicate that low birth weight and ... arthroplasty due to OA as adults. , According ... of 25 are diagnosed with clinical OA. Symptoms of ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
... its host, the respiratory pathogen Pseudomonas aeruginosa takes ... adds three small molecules to turn it into a key ... be published May 7 in mBio , the online ... Emory University School of Medicine, the University of Virginia, and ...
... , On May 3, 2013, the NOAA GOES infrared and visible ... of smoke from the fire. The smoke plume is seen blowing ... 17 seconds and shows the smoke plume from May 3 at ... created by the NASA GOES Project, located at NASA,s Goddard Space ...
... MARC (Maximizing Access to Research Careers) Program has announced ... of Sports Medicine (ACSM) 60th Annual Meeting & 4th ... from May 28 June 1, 2013. These awards ... and scientists from underrepresented groups into the mainstream of ...
Cached Biology News:Pathogen turns protein into a virulence factor in 1 easy step 2Pathogen turns protein into a virulence factor in 1 easy step 3MARC travel awards announced for the 2013 60th Annual ACSM Meeting & 4th World Congress 2
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
... Clone/PAD: ZMD.368. Immunogen: Synthetic ... of the human WNT2B/WNT13 protein. ... human mouse and rat WNT2B/WNT13 proteins. ... isoforms. Reactivity: Mouse Human Rat ...
Request Info...
... Peptide sequences: Two separate ... corresponding to the same sequence used ... antiserum (Catalog No. 160890) ... with Cayman's guanylate cyclase polyclonal antiserum ...
Biology Products: